Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…
We expect the ulcerative colitis (UC) market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio,…
Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs, where available) and a cell adhesion molecule (CAM) inhibitor (Takeda’s…
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…
MARKET OUTLOOK The ulcerative colitis (UC) market landscape is constantly evolving. The TNF-α inhibitors have the longest tenure among all biologics for UC; however, the launch of Takeda’s…
Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs where available) are the mainstay of biological treatment for moderate to…
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-ASAs), which are often effective…
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-ASAs), which are often effective…
We expect the ulcerative colitis (UC) market to grow steadily over the next decade. The availability of non-TNF biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) and the first oral JAK…
Epidemiology Data Slicer – Ulcerative Colitis
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-ASAs), which are often effective…
Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…